John W.M. Martens YOU? Author Swipe

Last 10y

APOBEC3B protein expression associates with poor prognosis for breast cancer patients with ER-positive disease Open

Maartje A. C. Schreurs, A. Mieke Timmermans, Michael A. Carpenter, Marcel Smid, Michael A. den Bakker , et al. · 2025

Table 1 from PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naïve Prostate Cancer Patients Open

Eshwari Dathathri, Fikri Abali, Michiel Stevens, Richell Booijink, Tanja C. van Dijk , et al. · 2025

Baseline characteristics

Figure S1 from PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naïve Prostate Cancer Patients Open

Eshwari Dathathri, Fikri Abali, Michiel Stevens, Richell Booijink, Tanja C. van Dijk , et al. · 2025

PSMA positivity was observed to be highest in LNCaP with 88% above the level of 200 and CK positivity of 100% above the level of 50. The cells of both PC3 and RWPE-1 (negative for PSMA) showed 0.9% positivity above 200 for PSMA and 100% CK…

Figure S3 from PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naïve Prostate Cancer Patients Open

Eshwari Dathathri, Fikri Abali, Michiel Stevens, Richell Booijink, Tanja C. van Dijk , et al. · 2025

Visualization of the nanowells and membrane using the VyCAP SPOT software (A) Imprint of IgG antibody printed onto a PVDF membrane using a nanowell array, is used to align and match the secreted proteins to the corresponding cell inside a …

Figure 1 from PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naïve Prostate Cancer Patients Open

Eshwari Dathathri, Fikri Abali, Michiel Stevens, Richell Booijink, Tanja C. van Dijk , et al. · 2025

Enumeration of CTCs based on CK and PSMA expression. A, Graph depicting the number of DAPI⁺ CD45⁻ CTCs as the following groups: CK⁻PSMA⁺ (yellow), CK⁺ PSMA⁻(orange), …

Figure 6 from PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naïve Prostate Cancer Patients Open

Eshwari Dathathri, Fikri Abali, Michiel Stevens, Richell Booijink, Tanja C. van Dijk , et al. · 2025

PSA secretions (pg/cell) from single CTC and total CTC captured in nanowell array from patients with mCNPC (n = 18). A, The PSMA⁺ PSA⁺ (in red) and PSMA⁻PSA⁺ (in yellow) indicate th…

Figure 3 from PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naïve Prostate Cancer Patients Open

Eshwari Dathathri, Fikri Abali, Michiel Stevens, Richell Booijink, Tanja C. van Dijk , et al. · 2025

Flow cytometry analysis of EpCAM-enriched DLA sample. A, Flow plot showing the forward and side scatter of the sample with a gate excluding small events (in black). B, CD45-APC vs. calcein AM scatter plot of the events with a…

Figure 4 from PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naïve Prostate Cancer Patients Open

Eshwari Dathathri, Fikri Abali, Michiel Stevens, Richell Booijink, Tanja C. van Dijk , et al. · 2025

Single-cell seeding of CTCs in a nanowell chip. Images of nanowells after seeding of sorted DLA samples. Nanowells 1 and 2 show calcein⁺ PSMA⁺ CD45⁻ cells and nanowells 3 and 4 show calcein⁺ PSMA…

Figure 2 from PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naïve Prostate Cancer Patients Open

Eshwari Dathathri, Fikri Abali, Michiel Stevens, Richell Booijink, Tanja C. van Dijk , et al. · 2025

Workflow schematically illustrating the DLA processing to obtain viable CTCs. (1) DLA enrichment using the reduced enrichment reagent (RER) protocol; (2) staining using anti–PSMA-PE, anti–CD45-APC, and viability dye calcein AM; (3) sorting…

Data from PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naïve Prostate Cancer Patients Open

Eshwari Dathathri, Fikri Abali, Michiel Stevens, Richell Booijink, Tanja C. van Dijk , et al. · 2025

PSA is the most common biomarker used in the screening and monitoring of prostate cancer. However, changes in PSA do not always reflect disease dynamics in every patient, and antihormonal agents may modulate its levels without significant …

Table S1 from PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naïve Prostate Cancer Patients Open

Eshwari Dathathri, Fikri Abali, Michiel Stevens, Richell Booijink, Tanja C. van Dijk , et al. · 2025

Adjusted prostate cancer organoid medium (APCOM) composition

Table S2 from PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naïve Prostate Cancer Patients Open

Eshwari Dathathri, Fikri Abali, Michiel Stevens, Richell Booijink, Tanja C. van Dijk , et al. · 2025

CTC recovery after sorting and seeding on nanowells

Figure S4 from PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naïve Prostate Cancer Patients Open

Eshwari Dathathri, Fikri Abali, Michiel Stevens, Richell Booijink, Tanja C. van Dijk , et al. · 2025

PSA protein calibration curve (A): Serial dilutions of PSA protein spotted on PVDF membrane, stained and visualized in FITC. (B): Calibration graph of PSA (pg/μm2) versus the normalized mean intensity of the spots (R2 = 0.97).

Figure S5 from PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naïve Prostate Cancer Patients Open

Eshwari Dathathri, Fikri Abali, Michiel Stevens, Richell Booijink, Tanja C. van Dijk , et al. · 2025

Steps used to determine the area of the PSA spots produced by single CTC. Images of the membranes with the PSA products from single CTC cells were segmented in Image J software (version 1.54g). Once the spots were segmented, the minimum an…

Figure S2 from PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naïve Prostate Cancer Patients Open

Eshwari Dathathri, Fikri Abali, Michiel Stevens, Richell Booijink, Tanja C. van Dijk , et al. · 2025

DLA samples isolated in nanowells (A): Example of a non-sorted DLA sample showing the presence of cell debris with non-specific staining in PE, FITC and APC channels, making it difficult to identify intact live CTC. (B): Example of sorted …

Figure 5 from PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naïve Prostate Cancer Patients Open

Eshwari Dathathri, Fikri Abali, Michiel Stevens, Richell Booijink, Tanja C. van Dijk , et al. · 2025

Measurement of PSA secretion of individual CTC captured on a membrane placed below the nanowell array. A, The image of the membrane detached from the nanowell array and stained with PSA-FITC and printed with anti–IgG-PE. The squares…

Figure 7 from PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naïve Prostate Cancer Patients Open

Eshwari Dathathri, Fikri Abali, Michiel Stevens, Richell Booijink, Tanja C. van Dijk , et al. · 2025

Distribution of CTC groups in the nanowells. A, Percentage of PSA-secreting and non-secreting cells detected in the nanowells and analyzed using the SPOT software. B, Percentage of PSMA⁺ and PSMA⁻ cells …

Figure S6 from PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naïve Prostate Cancer Patients Open

Eshwari Dathathri, Fikri Abali, Michiel Stevens, Richell Booijink, Tanja C. van Dijk , et al. · 2025

Correlation of PSA CTC vs PSA serum in the processed blood volume of 9 mCNPC patients in whom PSA-secreting CTC were identified. A weak positive correlation was observed with Spearman coefficient (ρ) = 0.28.

Circulating tumour cells & circulating tumour DNA in patients with resectable colorectal liver metastases (MIRACLE): a prospective, observational biomarker study Open

Lissa Wullaert, Maurice P.H.M. Jansen, Jaco Kraan, Yannick Meyer, Kelly R. Voigt , et al. · 2025

PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naïve Prostate Cancer Patients Open

Eshwari Dathathri, Fikri Abali, Michiel Stevens, Richell Booijink, Tanja C. van Dijk , et al. · 2025

PSA is the most common biomarker used in the screening and monitoring of prostate cancer. However, changes in PSA do not always reflect disease dynamics in every patient, and antihormonal agents may modulate its levels without significant …

Novel protocol for mapping virus integration sites in genes involved in therapy resistance Open

Michele Massimino, Zhangzan Huang, Jean Helmijr, Camilla Muritti, Anna Uijtdewillegen , et al. · 2025

A comparative study of four cell-free DNA assays for detecting circulating tumor DNA in early breast cancer Open

Charlotta Mulder, Elisabeth M. Jongbloed, Marte C. Liefaard, Stavros Makrodimitris, Daan Hazelaar , et al. · 2025

Early prediction of the response to neoadjuvant chemotherapy (NAC) enables tailoring treatment strategies to the specific needs of individual breast cancer patients. Circulating tumor DNA (ctDNA) has shown to be a prognostic factor for res…

Clinicopathological and molecular characterization of inflammatory breast cancer, the prospective INFLAME registry study Open

Jasper van Geel, Elisabeth M. Jongbloed, Jasmine Moustaquim, Gonneke van der Schoor, A. Elise van Leeuwen‐Stok , et al. · 2025

The pan-cancer proteome atlas, a mass spectrometry-based landscape for discovering tumor biology, biomarkers, and therapeutic targets Open

Jaco C. Knol, Mengge Lyu, Franziska Böttger, Madalena Monteiro, Thang V. Pham , et al. · 2025

Most cancer proteomics studies to date have focused on a single cancer type. We report The Pan-Cancer Proteome Atlas (TPCPA) based on data-independent acquisition mass spectrometry, to better understand cancer biology and identify therapeu…

Label‐Free Microscale Technologies for Isolation of Heterogeneous Circulating Tumor Cells Open

Gürhan Özkayar, Esma Derin, Georg R. Pesch, John W.M. Martens, Peter ten Dijke , et al. · 2025

The dissemination of primary solid tumor cells to distant organs, termed metastasis, is a major cause of cancer‐related deaths. Circulating tumor cells (CTCs), which can exist as individual cells or multicellular clusters, travel through t…

Outcomes of living donor liver transplant in elevated body mass index over a decade in the United States Open

Marie L. Jacobs, Matthew Byrne, Xueya Cai, Shan Gao, John W.M. Martens , et al. · 2025

Novel molecular biomarkers to guide treatment-decision making in metastatic urothelial cancer - A patient cohort analysis Open

Debbie Robbrecht, Youssra Salhi, John W.M. Martens, Maureen J.B. Aarts, Paul Hamberg , et al. · 2025

The current options and recent developments in the field of systemic therapy for advanced urothelial cancer (UC) patients, urges the need for selection criteria to identify the most optimal therapeutic option for individual patients. The m…

Novel Molecular Biomarkers to Guide Treatment Decision-making in Metastatic Urothelial Cancer—A Patient Cohort Analysis Open

Debbie Robbrecht, Youssra Salhi, John W.M. Martens, Maureen J.B. Aarts, Paul Hamberg , et al. · 2025

The current options and recent developments in the field of systemic therapy for advanced urothelial cancer (UC) patients urge the need for selection criteria to identify the most optimal therapeutic option for individual patients. The mol…

Cell‐free <span>DNA</span> aneuploidy score as a dynamic early response marker in prostate cancer Open

Khrystany T. Isebia, Anouk C. de Jong, Lisanne F. van Dessel, Vanja de Weerd, Corine M. Beaufort , et al. · 2025

Cell‐free circulating tumor DNA (ctDNA) has emerged as a promising biomarker for response evaluation in metastatic castration‐resistant prostate cancer (mCRPC). The current study evaluated the modified fast aneuploidy screening test‐sequen…

TransValid-A-Studie zur präoperativen, 5-FU-basierten Chemo-/Radiotherapie bei Rektumkarzinomen: Machbarkeit, Durchführbarkeit und erste Ergebnisse Open

John W.M. Martens · 2025

Die multizentrische TransValid-A-Studie (ClinTrials.gov: NCT03034473; DFG-gefördert; GZ: LI 1727/3-1) prüfte unter real-world-Bedingungen die Durchführbarkeit und Effizienz einer 5-FU-basierten präoperativen Chemo-/Radiotherapie (CRT) unte…

Fetching topic information...